Professor of Medicinal Chemistry at Newcastle University and Cancer Research Horizons, Director of MoSMed CDT and Editor-in-Chief of RSC Medicinal Chemistry
Mike Waring
Loading...
New paper out in J Med Chem showing that covalent targeting of C775 has the potential to treat osimertinib resistant lung cancer. Really proud of this work and the team that did it! @nudrugdiscovery.bsky.social @nucancer.bsky.social @crhorizons.bsky.social pubs.acs.org/doi/10.1021/...
New paper: We've always used TPGS in our micellar #DEL synthesis. This paper shows you can find better ones using @baonguyengroup.bsky.social surfactant map. Great work from Jake Odger et al pubs.rsc.org/en/Content/A...
Something makes me think that this invite might have been autogenerated...
It's official, our med chem Senior Research Associate @hannahstewart92.bsky.social is the world's fastest scientist @guinnessworldrecords.com guinnessworldrecords.com/world-record...
Starting the @mosmedcdt.bsky.social conference. It will get better from here!
Group trip to the pub / watch the bins being emptied.
This work also provides some hopefully useful information on how to generate and interpret SAR of covalent inhibitors.
New paper published today describing some SAR on EGFR inhibitors including an interesting effect of a pair of enantiomers on covalent biinding www.nature.com/articles/s42...
Prof. Mike Waring (@mikewaring.bsky.social), Chair of Medicinal Chemistry, Newcastle University #facesofscience #chemsky #sciencesky
